1. Home
  2. GRBK vs ADPT Comparison

GRBK vs ADPT Comparison

Compare GRBK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRBK
  • ADPT
  • Stock Information
  • Founded
  • GRBK N/A
  • ADPT 2009
  • Country
  • GRBK United States
  • ADPT United States
  • Employees
  • GRBK N/A
  • ADPT N/A
  • Industry
  • GRBK Homebuilding
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GRBK Consumer Discretionary
  • ADPT Health Care
  • Exchange
  • GRBK Nasdaq
  • ADPT Nasdaq
  • Market Cap
  • GRBK 2.9B
  • ADPT 2.6B
  • IPO Year
  • GRBK N/A
  • ADPT 2019
  • Fundamental
  • Price
  • GRBK $64.74
  • ADPT $17.36
  • Analyst Decision
  • GRBK Buy
  • ADPT Strong Buy
  • Analyst Count
  • GRBK 2
  • ADPT 10
  • Target Price
  • GRBK $71.00
  • ADPT $15.10
  • AVG Volume (30 Days)
  • GRBK 258.5K
  • ADPT 1.6M
  • Earning Date
  • GRBK 10-29-2025
  • ADPT 11-05-2025
  • Dividend Yield
  • GRBK N/A
  • ADPT N/A
  • EPS Growth
  • GRBK N/A
  • ADPT N/A
  • EPS
  • GRBK 7.63
  • ADPT N/A
  • Revenue
  • GRBK $2,113,173,000.00
  • ADPT $205,216,000.00
  • Revenue This Year
  • GRBK N/A
  • ADPT $34.41
  • Revenue Next Year
  • GRBK $6.60
  • ADPT $14.03
  • P/E Ratio
  • GRBK $8.49
  • ADPT N/A
  • Revenue Growth
  • GRBK 6.62
  • ADPT 21.60
  • 52 Week Low
  • GRBK $50.57
  • ADPT $4.27
  • 52 Week High
  • GRBK $77.93
  • ADPT $17.89
  • Technical
  • Relative Strength Index (RSI)
  • GRBK 40.03
  • ADPT 63.04
  • Support Level
  • GRBK $63.73
  • ADPT $16.59
  • Resistance Level
  • GRBK $69.73
  • ADPT $17.40
  • Average True Range (ATR)
  • GRBK 2.18
  • ADPT 0.79
  • MACD
  • GRBK -0.23
  • ADPT -0.07
  • Stochastic Oscillator
  • GRBK 35.45
  • ADPT 80.35

About GRBK Green Brick Partners Inc.

Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: